HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Lilian Abbo, MD, FIDSA Keith S. Kaye, MD, MPH Jason M. Pogue, PharmD Released: February 18, 2022